These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16392792)

  • 1. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
    Pirard B; Matter H
    J Med Chem; 2006 Jan; 49(1):51-69. PubMed ID: 16392792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
    Lukacova V; Zhang Y; Kroll DM; Raha S; Comez D; Balaz S
    J Med Chem; 2005 Apr; 48(7):2361-70. PubMed ID: 15801829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
    Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
    Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.
    Zhu Z; Mazzola R; Sinning L; McKittrick B; Niu X; Lundell D; Sun J; Orth P; Guo Z; Madison V; Ingram R; Beyer BM
    J Med Chem; 2008 Feb; 51(4):725-36. PubMed ID: 18247549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins.
    Matter H; Schwab W
    J Med Chem; 1999 Nov; 42(22):4506-23. PubMed ID: 10579815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach.
    Terp GE; Cruciani G; Christensen IT; Jørgensen FS
    J Med Chem; 2002 Jun; 45(13):2675-84. PubMed ID: 12061871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.
    Mazzola RD; Zhu Z; Sinning L; McKittrick B; Lavey B; Spitler J; Kozlowski J; Neng-Yang S; Zhou G; Guo Z; Orth P; Madison V; Sun J; Lundell D; Niu X
    Bioorg Med Chem Lett; 2008 Nov; 18(21):5809-14. PubMed ID: 18835710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors.
    Rush TS; Powers R
    Curr Top Med Chem; 2004; 4(12):1311-27. PubMed ID: 15320728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IK682, a tight binding inhibitor of TACE.
    Niu X; Umland S; Ingram R; Beyer BM; Liu YH; Sun J; Lundell D; Orth P
    Arch Biochem Biophys; 2006 Jul; 451(1):43-50. PubMed ID: 16762314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
    Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
    J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potent and selective TACE inhibitors via the S1 pocket.
    Condon JS; Joseph-McCarthy D; Levin JI; Lombart HG; Lovering FE; Sun L; Wang W; Xu W; Zhang Y
    Bioorg Med Chem Lett; 2007 Jan; 17(1):34-9. PubMed ID: 17064892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme.
    Wei S; Kashiwagi M; Kota S; Xie Z; Nagase H; Brew K
    J Biol Chem; 2005 Sep; 280(38):32877-82. PubMed ID: 16079149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of binding with matrix metalloproteinases.
    Gupta SP; Patil VM
    Exp Suppl; 2012; 103():35-56. PubMed ID: 22642189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity.
    Sarkate AP; Murumkar PR; Lokwani DK; Kandhare AD; Bodhankar SL; Shinde DB; Bothara KG
    SAR QSAR Environ Res; 2015; 26(11):905-23. PubMed ID: 26588187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8).
    Pochetti G; Montanari R; Gege C; Chevrier C; Taveras AG; Mazza F
    J Med Chem; 2009 Feb; 52(4):1040-9. PubMed ID: 19173605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of the C(α) substituent in the selective inhibition of matrix metalloproteinases 1 and 9.
    Domingo R; Chibale K; Sturrock ED
    Biol Chem; 2011 Nov; 392(11):1003-10. PubMed ID: 21972974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex.
    Wisniewska M; Goettig P; Maskos K; Belouski E; Winters D; Hecht R; Black R; Bode W
    J Mol Biol; 2008 Sep; 381(5):1307-19. PubMed ID: 18638486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin.
    Dunten P; Kammlott U; Crowther R; Levin W; Foley LH; Wang P; Palermo R
    Protein Sci; 2001 May; 10(5):923-6. PubMed ID: 11316871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of properties of tumor necrosis factor-alpha converting enzyme (TACE) and some matrix metalloproteases (MMPs) in catalytic domains.
    Zhao Y; Feng W; Yang Y; Ling L; Chen R
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(6):637-9. PubMed ID: 17357475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.
    Rosner KE; Guo Z; Orth P; Shipps GW; Belanger DB; Chan TY; Curran PJ; Dai C; Deng Y; Girijavallabhan VM; Hong L; Lavey BJ; Lee JF; Li D; Liu Z; Popovici-Muller J; Ting PC; Vaccaro H; Wang L; Wang T; Yu W; Zhou G; Niu X; Sun J; Kozlowski JA; Lundell DJ; Madison V; McKittrick B; Piwinski JJ; Shih NY; Arshad Siddiqui M; Strickland CO
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1189-93. PubMed ID: 20022498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.